10.22376/ijpbs.2019.10.1.p1-12 Volume 3 Issue 1 2012 (January - March) Cyclooxygenase-2 is being treated as one of the chief anti-cancer targets for colorectal, lung, breast, prostate and head/neck cancer. The focus of this study is to discover new ligand molecules, which can be used as a potential drug against Cyclooxygenase-2. The structure of Cyclooxygenase-2 of lessThan i greaterThan Homo sapiens lessThan /i greaterThan was modeled using "MODELLER". The FDA approved and experimental level drugs are available in DrugBank3.0 database was screened against Cyclooxygenase-2 using the virtual screening facility offered by PYR-X0.8 software. Molecular docking studies were performed using AutoDock Wizard and the results were analyzed critically with the help of AutoDock tools 1.4.5. Virtual Screening and Molecular Docking Analysis revealed four molecules. Namely, N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl) phthalazin-6-yl]benzamide, 6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-Yl)-3-Methylquinoline-4-Carboxylic Acid, Eletriptan and Tamibarotene. Ezhilarasan V., Chinnathambi. V., Jnarthanan V., Yazhini K.A And Sridhar S. Cyclooxygenase-2; Anti-cancer drugs; molecular modeling and docking; virtual screening. 379-391